158 related articles for article (PubMed ID: 20507734)
1. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.
Huang X; Yu HS; Chen Z; Li JL; Hu ZM; Gao JM
Chin J Cancer; 2010 Jun; 29(6):611-6. PubMed ID: 20507734
[TBL] [Abstract][Full Text] [Related]
2. [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
Chen Z; Tan WL; Huang X; Liang ZK; Xu CX; Gao JM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):936-40. PubMed ID: 20501361
[TBL] [Abstract][Full Text] [Related]
3. [Intravesical anchoring of streptavidin-tagged interleukin-4 fusion protein for immunotherapy of mouse superficial bladder cancer].
Zhang Z; Xu XL; Ma L; Li JL; Hu ZM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):331-5. PubMed ID: 22883451
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer.
Zhang Z; Xu X; Zhang X; Chen X; Chen Q; Dong L; Hu Z; Li J; Gao J
Acta Oncol; 2011 Oct; 50(7):1111-8. PubMed ID: 21247263
[TBL] [Abstract][Full Text] [Related]
5. A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF.
Hu Z; Tan W; Zhang L; Liang Z; Xu C; Su H; Lu J; Gao J
J Cell Mol Med; 2010 Jun; 14(6B):1836-44. PubMed ID: 19627402
[TBL] [Abstract][Full Text] [Related]
6. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
8. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
[TBL] [Abstract][Full Text] [Related]
9. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
Zhang X; Shi X; Li J; Hu Z; Guo F; Huang X; Zhang Z; Sun P; Jing Y; Gao J; Tan W
Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685
[TBL] [Abstract][Full Text] [Related]
10. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
[TBL] [Abstract][Full Text] [Related]
11. Tumor inhibitory effects of intravesical Ganoderma lucidum instillation in the syngeneic orthotopic MB49/C57 bladder cancer mice model.
Yuen JWM; Mak DSY; Chan ES; Gohel MDI; Ng CF
J Ethnopharmacol; 2018 Sep; 223():113-121. PubMed ID: 29783018
[TBL] [Abstract][Full Text] [Related]
12. [Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice].
Peng J; Shi X; Chen D; Liang Z; Lan K; Gao J; Tan W
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):807-11. PubMed ID: 22699059
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma.
Arnold J; de Boer EC; O'Donnell MA; Böhle A; Brandau S
J Immunother; 2004; 27(2):116-23. PubMed ID: 14770083
[TBL] [Abstract][Full Text] [Related]
15. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
18. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy.
McAveney KM; Gomella LG; Lattime EC
Cancer Immunol Immunother; 1994 Dec; 39(6):401-6. PubMed ID: 8001028
[TBL] [Abstract][Full Text] [Related]
19. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
Luo Y; Han R; Evanoff DP; Chen X
Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]